Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon Program [Seeking Alpha]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Seeking Alpha
RCKT's bullish thesis hinges on a high-probability LAD-1 approval in March 2026 and the pivotal Danon's disease trial resuming with an amended, safer protocol. Risk-adjusted DCF values Danon's and LAD-1 programs at ~$700M, far exceeding the current $151M EV, even under conservative or bear-case assumptions. Near-term catalysts include LAD-1's PDUFA date and potential $150M PRV, providing non-dilutive capital and extending cash runway into 2027. Nadzeya Haroshka/iStock via Getty Images Rocket Pharmaceuticals ( RCKT Rating: Buy Price Target (DCF): $17 Current Price: $3.54 Executive Summary: Deep Dislocation Offers Asymmetric Upside We are initiating coverage on Rocket Pharmaceuticals with a Buy rating and a $17 price target (2-3 More on my IG service Premium service reviews "The best I have ever seen in the biotech space...I have been in the biotech investing space for a while and have not seen a service like the one Dr. Bhavneesh provides." "Great service wit
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket Pharmaceuticals (NASDAQ:RCKT) was upgraded by analysts at TD Cowen to a "hold" rating.MarketBeat
- Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare ConferenceBusiness Wire
RCKT
Earnings
- 11/6/25 - Beat
RCKT
Sec Filings
- 11/20/25 - Form 4
- 11/20/25 - Form 4
- 11/20/25 - Form 4
- RCKT's page on the SEC website